drugset / Trial / NCT01015222
Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the highest tolerable dose of the combination of dasatinib, bevacizumab, and paclitaxel with or without Methylnaltrexone that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.
Timeline
- Start
- 2009-11
- Primary completion
- 2021-05-27
- Completion
- 2021-05-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Paclitaxel | Small molecule | 40 mg/m2 | Intravenous |
| Subject | dasatinib anhydrous | Small molecule | 50 mg | Oral |